Source: SEBI
What would have to hold for each case — not a price target or a projected figure. CapitSignal does not forecast where this stock trades.
The company successfully expands its distribution network in Africa.
Claroid Pharmaceuticals Limited has over 30 distributors across multiple countries, indicating potential for growth in semi-regulated markets.
Regulatory approvals for new products are obtained without delays.
The company has made applications for regulatory approvals in various regions, which could enhance its product offerings and revenue.
Revenue growth continues at the current trajectory.
The company reported significant revenue growth of 70.23% in Fiscal 2026, indicating a strong operational performance.
The company maintains its current customer base without significant losses.
Top ten customers contributed over 62% of total sales in Fiscal 2026, highlighting customer concentration risk.
The company loses a major customer or experiences a decline in export sales.
The company is significantly dependent on its top ten customers, and loss of any could materially affect its business.
Regulatory compliance issues arise, leading to operational disruptions.
The company has faced delays in obtaining approvals and is subject to various regulatory requirements, which could adversely impact operations.